US prevalence
~30M US adults
Source: AASM
Loading content…
Condition
Obstructive Sleep Apnea
OSA is breathing interruption during sleep, often driven by obesity. In December 2024, Zepbound became the first FDA-approved drug for moderate-to-severe OSA in adults with obesity. Zepbound is FDA-approved (Dec 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity. Evidence grade: A. In the SURMOUNT-OSA trials, tirzepatide reduced the apnea-hypopnea index (AHI) by roughly 25-30 events per hour at 52 weeks, with a substantial fraction of patients reaching disease remission. CPAP remains standard of care — Zepbound is positioned as adjunct or alternative for patients who cannot tolerate CPAP. Other GLP-1s (Wegovy, semaglutide) are not approved for OSA but may produce indirect benefit via weight loss.
Quick answer
UpdatedObstructive sleep apnea (OSA) is a sleep disorder where airway collapses during sleep, causing repeated breathing pauses. Estimated 30 million US adults have OSA (many undiagnosed). Obesity is the strongest modifiable risk factor. In 2024, FDA approved Zepbound (tirzepatide) for moderate-to-severe OSA in adults with obesity — first GLP-1 with this specific indication. SURMOUNT-OSA trial: 51% improvement in apnea events at 52 weeks.
- US prevalence: ~30 million adults
- AASM data; many undiagnosed
- Obesity link: 70% of OSA patients have obesity
- Each 10% weight gain → 6× higher OSA risk
- Zepbound efficacy: 51% improvement in apnea events
- SURMOUNT-OSA trial, 52 weeks (FDA-approved 2024)
- CPAP-discontinuation: Possible after 10-15% weight loss
- Sleep retest after weight loss often shows OSA resolution
- First-line therapy: CPAP (continuous positive airway pressure)
- Weight loss + GLP-1 are adjuncts or replacements